Paul L. Nguyen, MD, on Salvage Radiotherapy, GnRH Agonist, Abiraterone, Prednisone, and Apalutamide in Prostate Cancer Treatment

Posted: Wednesday, March 8, 2023

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses the clinical implications of findings from the FORMULA-509 study, which suggest that, adding acetate/prednisone and apalutamide to salvage radiotherapy, plus 6 months of androgen-deprivation therapy, may improve outcomes, particularly in the subgroup of patients with a prostate-specific antigen level higher than 0.5 ng/mL.

---